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Abstract
Purpose: Early detection of tumor treatment responses represents an unmet clinical need with
no approved noninvasive methods. DAB4, or its chimeric derivative, chDAB4 (APOMAB®) is an
antibody that targets the Lupus associated antigen (La/SSB). La/SSB is over-expressed in
malignancy and selectively targeted by chDAB4 in cancer cells dying from DNA-damaging
treatment. Therefore, chDAB4 is a unique diagnostic tool that detects dead cancer cells and
thus could distinguish between treatment responsive and nonresponsive patients.
Procedures: In clinically relevant tumor models, mice bearing subcutaneous xenografts of
human ovarian or lung cancer cell lines or intraperitoneal ovarian cancer xenografts were
untreated or given chemotherapy followed 24h later by chDAB4 radiolabeled with [89Zr]ZrIV.
Tumor responses were monitored using bioluminescence imaging and caliper measurements.
[89Zr]Zr-chDAB4 uptake in tumor and normal tissues was measured using an Albira SI Positron-
Emission Tomography (PET) imager and its biodistribution was measured using a Hidex
gamma-counter.
Results: Tumor uptake of [89Zr]Zr-chDAB4 was detected in untreated mice, and uptake
significantly increased in both human lung and ovarian tumors after chemotherapy, but not in
normal tissues.
Michael P. Brown and Alexander H. Staudacher are Co-Senior Authors.
Correspondence to: Vasilios Liapis; e-mail: vasilios.liapis@sa.gov.au
Conclusion: Given that tumors, rather than normal tissues, were targeted after chemotherapy,
these results support the clinical development of chDAB4 as a radiodiagnostic imaging agent
and as a potential predictive marker of treatment response.
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Introduction
The care and treatment of cancer patients places an intense
demand on healthcare systems globally. Standard treatment
regimens for locally advanced or metastatic cancers usually
employ radiotherapy, cytotoxic chemotherapy or both.
Often, however, the treatment is not sufficiently effective
and may represent a significant personal and socioeconomic
burden for patients if it is both toxic and ineffective.
Therefore, a robust method for early or interim determina-
tion of tumor responses may allow patients to continue
effective therapy, discontinue ineffective therapy and also
aid in go/no-go decision making in anticancer drug
development.
Current methods for determining tumor responses are
based on measuring changes in tumor dimensions using
computed tomography (CT), magnetic resonance imaging
(MRI), and ultrasound according to Response Evaluation
Criteria in Solid Tumors (RECIST) [1] or measuring
FDG avidity on 18F-FDG positron emission tomography
(PET)/(PET/CT) scans using PET Response Criteria in
Solid Tumors (PERCIST) or tumor-specific criteria [2,
3]. Although there is no established role for FDG-PET in
chemotherapy response monitoring of either lung or
ovarian cancers [4, 5], FDG-PET and SPECT studies in
nonsmall cell lung carcinoma (NSCLC) patients after a
first cycle of platinum-based chemotherapy have been
informative. For example, tumor responders, who were
defined as having a decrease of at least 10 % in
standardized uptake value (SUV) of tumor FDG uptake,
had the best survival prospects [5, 6]. Nevertheless, the
sensitivity and specificity of FDG-PET/CT for therapy
response monitoring may be limited by such tumor
variables as expression of glucose transporters [7], or
tissue inflammation or infection, both of which may also
be FDG avid [8]. Therefore, there has been great interest
in the field of molecular imaging to develop selective,
robust, and clinically applicable in vivo imaging markers
of therapy-induced tumor cell death [9–11].
For example, in NSCLC patients who received 99mTc-
labeled annexin V as a marker of cell death, early
chemotherapy-induced tumor-specific annexin V uptake on
SPECT significantly correlated with later RECIST-defined
tumor responses although some patients with RECIST-
defined stable disease also had tumor annexin V uptake
[12]. However, increased tumor uptake of annexin V
appeared to depend on the exact time after the start of
chemotherapy and the type and stage of the cancer treated,
and high accumulation of annexin V in the kidneys was also
evident [10, 13].
Further among the cited in vivo imaging markers of
therapy-induced tumor cell death that may possess the
requisite qualities is DAB4, which originated as a mouse
monoclonal antibody (mAb) [14, 15] and which has been
reformatted as a chimeric mAb (chDAB4; APOMAB®) [16,
17]. In either format, the DAB4 and chDAB4 mAbs target
the ubiquitously and abundantly expressed ribonucleopro-
tein, Lupus-associated (La)/Sjögren Syndrome-B (SSB)
antigen, which is essential for life [18, 19]. As a multifunc-
tional RNA binding protein, La/SSB protects nascent RNAs
from exonucleases enabling their maturation [20], and also
has roles promoting both microRNA biogenesis [21] and
translation of select mRNAs as an IRES transacting factor
(ITAF) [22]. Consequently, as we and others have shown,
La/SSB is overexpressed in many different cancers [23–27]
and contributes to the malignant process [28].
La/SSB only becomes accessible for antibody binding in
cells that have lost membrane integrity, particularly in
apoptotic and necrotic cancer cells, making DAB4 a dead
tumor cell–targeting mAb, particularly after DNA-damaging
anticancer treatment [14, 15]. The La/SSB protein is highly
conserved between mice and humans and DAB4 binds to
both mouse and human forms of La/SSB. We have shown
both in vitro and in vivo that DAB4 binds with high
specificity to dead tumor cells [23, 29]. We drew on this
tumor-targeting property to radiolabel DAB4 with 111In for
tumor imaging [29, 30] and with 90Y [15], 177Lu [27] and
227Th [31] for antitumor therapy by exploiting the phenom-
enon of β- and α-radiation crossfire [32].
In preparation for a newly commenced clinical
radiodiagnostic imaging trial, the variable region sequences
of murine DAB4 were genetically fused to the constant
region sequences of human IgG1 to generate chimeric
DAB4 (chDAB4) [17]. We radiolabeled chDAB4 with the
positron-emitting radionuclide Zirconium-89 ([89Zr]ZrIV) so
that the radioimmunoconjugate could be used for noninva-
sive PET imaging. The physical half-life of [89Zr]ZrIV of 3.3
days is similar to the biological half-life of mAbs, so the
radionuclide is well suited for radiolabeling mAbs, making it
possible to obtain PET images with desirable contrast
between tumor uptake and normal tissue background.
Consequently, [89Zr]ZrIV has been used extensively for
radiolabeling antibodies for clinical immunoPET studies
[33, 34].
In this study, the ability of [89Zr]Zr-chDAB4 to selec-
tively bind to dead tumor cells in human xenografts of lung
Liapis V. et al.: APOMAB® Detects Tumour Cell Death Following Chemotherapy in vivo 915
and ovarian cancer after chemotherapy was examined using
PET imaging. This preclinical validation study supports the
use of chDAB4 as a diagnostic tool for detecting tumor
responses to first line platinum-based chemotherapy in lung
and ovarian cancer patients.
Materials and Methods
Cell Culture and Antibodies
The A2780 ovarian cancer cell line was purchased from
ATCC (USA) and the H460 large cell lung carcinoma cell
line was a gift from Associate Professor Carleen Cullinane
(Peter MacCallum Cancer Centre, Australia) and both were
authenticated by short tandem repeat testing using the
AmpFISTR Identifier Kit (ThermoFisher Scientific) by SA
Pathology (Adelaide, South Australia). Raji cells were
purchased from CellBank (Australia) and Jurkat cells were
kindly provided by Professor Andrew Zannettino (Myeloma
Research Laboratory, University of Adelaide, Australia). All
cell lines were cultured in RPMI-1640 which contained
penicillin and streptomycin (Sigma-Aldrich) and 10 % foetal
calf serum (FCS) (Bovogen Biologicals, Victoria, Australia).
Cells were negative for mycoplasma using MycoAlert®
Mycoplasma Detection Kit (Lonza, Basel, Switzerland). The
generation of luciferase tagged H460 and A2780 cells was
performed as described previously [35–37]. Chimeric DAB4
(chDAB4), resulting from the genetic fusion of the variable
region sequences of murine DAB4 to the constant region
sequences of human IgG1 (huIgG1) was created at CSIRO
Manufacturing and produced using the CHO-XL99 system
at the National Biologics Facility, Australian Institute for
Bioengineering and Nanotechnology, University of Queens-
land (Queensland, Australia) [16, 17]. The CH2 domain of
chDAB4’s huIgG1 Fc harbors the K322A mutation, which
can abrogate complement-dependent cytotoxicity (CDC) and
attenuate antibody-dependent cytotoxicity (ADCC) [38].
Flow Cytometry Analysis of chDAB4 Binding to
H460 and A2780 Cells
A2780 and H460 cells were treated with increasing
concentrations of cisplatin (Hospira, Australia) for 48 h,
collected, washed twice by centrifugation at 900g for 5 min
with FACS buffer (2.5 % FCS, 0.04 % sodium azide in
PBS) and incubated with 5 μg/mL chDAB4 or human IgG
(Intragram P; as control) for 30 min. Cells were washed and
incubated with 2 μg/mL goat antihuman IgG Alexa Fluor®
647 (ThermoFisher Scientific, USA) for 20 min, washed
further, incubated for 10 min with 0.5 μg/mL Propidium
Iodide (PI) (Sigma-Aldrich) and analyzed by flow cytometry
using a BD Accuri flow cytometer (BD Biosciences,
Franklin Lakes, NJ, USA). Gating was set at 2 % positive
events in the isotype control sample. Specific binding was
calculated as the difference in Mean Fluorescence Intensity
(MFI) between chDAB4 and the isotype control antibody
and expressed as the net MFI, which was calculated from
triplicate samples.
Chelator Conjugation and Radiolabeling of
chDAB4 With [89Zr]ZrIV
[89Zr]ZrIV oxalate was produced by SAHMRI via proton
irradiation of a 89Y target on a PETtrace 880 cyclotron (GE
Healthcare) and purified on an Alceo solid target processing
system (Comecer, Italy) as described previously [39]. In this
preclinical study, the chDAB4 mAb was conjugated to the
bifunctional chelator p-isothiocyanatobenzyl-deferoxamine
(DFO-pPhe-NCS) (Macrocyclics, Texas, USA) as described
[40] and radiolabeled with [89Zr]ZrIV. For simplicity of
expression, the [89Zr]ZrIV-radiolabeled DFO-pPhe-NCS
conjugate of chDAB4 is henceforth referred to as [89Zr]Zr-
chDAB4. On the other hand, based on recent preclinical data
comparing the DFO-pPhe-NCS conjugate of chDAB4 with a
newly developed DFO-Sq (H3DFOSqOEt) conjugate of
chDAB4 [41], a [89Zr]ZrIV-radiolabeled DFO-Sq conjugate
of chDAB4 was employed in the ongoing phase 1 clinical
trial (ANZCTR No. 12620000622909) radiolabeled with
[89Zr]ZrIV as described previously [40]. The radiolabeled
antibodies were washed and concentrated using 50 kDa
MWCO centrifuge filters and resuspended in sterile PBS for
injection. Instant thin layer chromatography (ITLC) with
25 mM citrate buffer (pH 5.5) as a mobile phase was used to
measure the amount of free [89Zr]ZrIV in the preparation,
which was G1 % of total activity (Rf G0.2 [bound [
89Zr]ZrIV]
vs Rf 90.7 [free [
89Zr]ZrIV)]).
Cell Binding Assays
A modified version of the Lindmo binding assay [42] was
used to determine the immunoreactive fraction (IRF) of the
radiolabeled chDAB4. H460 human lung cancer cells were
fixed and permeabilized as previously described to expose
the La/SSB protein [14, 15], resuspended in PBS with 1 %
FCS and serially diluted from 5 × 107 to 3.9 × 106 cells in
0.5mL in duplicate. 500 ng/mL of radiolabeled antibody in
0.5 mL PBS with 1 % FCS was added to the cell
suspensions and incubated at 4 °C overnight. The cells were
pelleted by centrifugation at 900g and 0.5 mL of the
supernatant from each sample was placed in a separate tube.
The radioactivity in the cell pellets and the supernatant was
measured using an automatic Gamma Counter (Hidex,
Finland). The inverse cell concentration (mL/cells in sample)
was plotted against the total activity (activity in supernatant
+ activity in pellet)/specific binding (total bound) and the
linear regression was extrapolated to calculate interception
of the y-axis where x = 0 and expressed as a percentage (IRF
= 100 % × 1/y[x=0]). The binding affinity of conjugated and
radiolabeled chDAB4 was compared to the intact, unlabeled
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chDAB4 using a La/SSB-specific ELISA as described
previously [16].
In Vitro Assays for Complement Dependent
Cytotoxicity (CDC), Antibody Dependent Cellular
Cytotoxicity (ADCC) and Cytokine Release
In the CDC assay, CD20+ Raji cells or CD20- Jurkat cells
were harvested, washed and added to each well of a 96-well
U-bottom plate at 105 cells/well in RPMI-1640 with 10 %
rabbit serum as the source of complement. The CD20-
specific chimeric mAb, rituximab, was used as a positive
control, and medium alone and the EGFR-specific chimeric
mAb, cetuximab, were used as negative controls. The mAbs
were added at a concentration of 15, 1.5, 0.15 or 0.015 μg/
mL in RPMI-1640 with 10 % rabbit serum and incubated for
2 h at 37 °C. Thiazolyl Blue Tetrazolium Bromide at a final
concentration of 0.4 mg/mL was added per well and the
plate incubated for 1 h at 37 °C with 5 % CO2. The plate
was centrifuged at 300g for 3 min, the supernatant was
removed, and the resulting crystals resuspended in 150 μL
isopropanol. Absorbance was measured at 570 nm using a
FLUOStar Omega plate reader.
ADCC was examined using the Promega ADCC Reporter
Bioassay kit. The assay uses genetically modified Jurkat
effector cells, which stably express the high-affinity V158F
receptor variant of FcγRIIIa together with a reporter gene
construct comprising a nuclear factor of activated T-cells
(NFAT) response element driving firefly luciferase expres-
sion. Binding to FcγRIIIa via the mAb Fc domain results in
detectable luciferase expression and induction of ADCC.
CD20+ Raji cells were used as the target cells. Permeabilized
H460 cells, which are strongly bound by chDAB4, were also
used as target cells. In a 96-well plate, chDAB4 or rituximab
were added at 3 μg/mL in triplicate. The antibodies were
serially diluted 1:2.5 to achieve final concentrations of 0,
0.002, 0.005, 0.012, 0.03, 0.08, 0.19, 0.48, 1.2, or 3 μg/mL.
The target cells were added to each well followed by effector
cells and incubated for 6 h at 37 °C with 5 % CO2. Plates
were equilibrated to room temperature for 15 min before the
Bio-Glo Luciferase Assay Reagent was added, incubated for
45 min and luminescence measured using a FLUOstar
Omega plate reader.
For the cytokine release assay (CRA), fresh blood was
taken from five volunteer donors. Peripheral blood mono-
nuclear cells (PBMCs) were isolated using density gradient
centrifugation with Lymphoprep (Alere Technologies) as per
manufacturer’s instructions and seeded at 105 cells/well in a
96-well U-bottom plate. In duplicate, cells were treated with
increasing doses of chDAB4 or 15 μg/mL anti-CD3
antibody (clone OKT3; prepared in-house) as a positive
control for 24 h at 37°C with 5 % CO2. The following day,
cells were pelleted and 100 μL of supernatant per well was
analyzed for cytokine levels using the LEGENDplex Human
Inflammation Panel 1 (Biolegend) following the manufac-
turer’s instructions.
Animal Experiments
The SAHMRI Animal Ethics Committee, (Adelaide, Aus-
tralia) approved all animal experiments, which were con-
ducted following institutional ethical guidelines. Six to ten-
week-old female NOD scid gamma-null (NSG) mice were
inoculated subcutaneously in the right flank with 5×106
A2780 or H460 tumor cells in a 1:1 ratio of Matrigel/PBS.
For the intraperitoneal ovarian cancer model, 5×106 A2780
cells in 100 μL PBS were injected into the intraperitoneal
cavity.
The IVIS® Spectrum Imaging system (PerkinElmer,
Massachusetts, USA) was used for noninvasive monitoring
of tumor growth of the luciferase-expressing cell lines. Mice
were given intraperitoneal injections (i.p.i.) with 100 μL of
D-Luciferin solution at 150 mg/kg (Pierce Biotechnology,
IL, USA) and then gas-anesthetized with isoflurane (Veter-
inary Companies of Australia, NSW, Australia). Images
were acquired for 1–30 sec (representative images are shown
at 1 sec, 20 min after D-Luciferin by i.p.i.) and the photon
emission transmitted from mice was captured and quantified
as photons/sec/cm2 using Living Image Software (version
4.7.2; Perkin Elmer, Massachusetts, USA). Tumor growth
was also measured using electronic calipers with tumor
volume determined using the calculation (a2 x b)/2, where a
is the shortest diameter and b is the longest diameter of the
tumor.
Mice were randomly allocated to treatment groups
when the subcutaneous tumors reached approximately 50
mm3, or 7 days after intraperitoneal injection of A2780
cells. Mice were untreated or treated by i.p.i. with 4
mg/kg cisplatin on Day 0. The day following chemo-
therapy (Day 1), mice bearing subcutaneous tumors were
given 6 MBq/50 μg [89Zr]Zr-chDAB4 by intravenous
injection (i.v.i.) while mice bearing ascitic A2780 tumors
were given 6 MBq/75 μg of [89Zr]Zr-chDAB4 by i.v.i..
As a blocking control, mice bearing H460 tumors were
given 250 μg of unlabeled chDAB4 i.v.i. 1 h before the
[89Zr]Zr-chDAB4 injection. Mice were monitored daily,
and tumor volume measured at least three times per
week via bioluminescence imaging and caliper measure-
ment. At the end of the experiment, mice were humanely
killed by cervical dislocation, and organs were removed,
weighed and radiation counts were measured with
background and decay corrected using a Hidex gamma-
counter for accumulation of [89Zr]ZrIV.
Animal PET and MRI Scanning
Mice were anesthetized with 2 % isoflurane and scanned
for 10 min using the Albira Si PET-SPECT small animal
scanner (Bruker Biospin GmbH, Valencia, Spain), with a
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submillimetric resolution of 0.7 mm. Using the PMOD
imaging suite (PMOD technologies, Switzerland), regions
of interest were manually drawn around the tumor from
the Maximum Intensity Projection (MIP) sections assisted
by the automatic 3D setting in PMOD software. Tumor
margins and thresholds were automatically detected by
the software, which includes a standardized cut off
determined by PMOD. These tumor margins and cut
off thresholds were used to analyze the radiotracer
accumulation within the tumor. At the end of the study,
2 mice with intraperitoneal A2780 tumors underwent
MRI imaging using the T2 weighted RARE spin echo
sequence on the Bruker Icon 1T benchtop MRI system.
The ITK Snap software was used to segment the scans
[43].
PET/CT Imaging of Patients
Based on the demonstration of superior preclinical PET
imaging qualities of the [89Zr]Zr-labeled DFO-Sq conju-
gate of chDAB4 compared to its DFO-pPhe-NCS
conjugate [41], we adopted the DFO-Sq conjugate of
chDAB4 in a recently commenced phase I clinical PET
imaging trial of [89Zr]Zr-chDAB4. This trial was ap-
proved by the Central Adelaide Local Health Network
Human Research Ethics Committee and is registered as
No. 12620000622909 29/05/2020 with the Australian and
New Zealand Clinical Trials Registry (ANZCTR) https://
w w w . a n z c t r . o r g . a u / T r i a l / R e g i s t r a t i o n /
TrialReview.aspx?id=379693. Patients with advanced
lung cancer received a single intravenous injection of a
1.2 mg mass dose of the DFO-Sq conjugate of chDAB4,
which had been labeled with 37 MBq [89Zr]ZrIV. Patients
underwent serial PET/CT scans on a Siemens Biograph
mCT Flow after having a standard FDG-PET/CT scan on
the same scanner within the previous 7–14 days. All
patients provided and signed informed consent to
participate in the study.
Statistical Analysis
Statistical analyses were performed using GraphPad
Prism (v7.0) software. Comparison of groups was
performed by two-way t-test or intergroup comparisons
made by two-way Analysis of Variance (ANOVA). Data
are shown as mean ± Standard Error of the Mean (SEM).
Statistical significance was reached when p G 0.05, with
* representing p G 0.05, ** p G 0.01, *** p G 0.001, and
**** p G 0.0001. All methods and studies were
performed in accordance with the guidelines and regula-
tions stated by the University of South Australia, the
University of Adelaide, SAHMRI and the Royal Ade-
laide Hospital.
Results
chDAB4 Binds to Cisplatin-Treated Dead H460
Lung Cancer Cells and A2780 Ovarian Cancer
Cells In Vitro
The A2780 and H460 cell lines were untreated or treated for
48 h with increasing doses of cisplatin and the binding of
chDAB4, or the human IgG control, to dead (PI+) cells was
assessed. For both cell lines, cisplatin treatment increased
cell death in a dose-dependent manner (Fig. 1a). Cisplatin
also increased the percentages of chDAB4-bound dead
tumor cells and, at the highest dose of 10 μg/mL of cisplatin,
985 % of H460 cells and 80 % of A2780 cells were PI+ and
bound by chDAB4 (Fig. 1b). This dose-dependent increase
in proportions of chDAB4-bound dead tumor cells was
matched by proportionate increases in the per cell binding of
chDAB4, which was measured as increasing mean fluores-
cence intensity (MFI) of dead tumor cell-bound chDAB4
with increasing cisplatin dose (Fig. 1c). These data con-
firmed that chDAB4 bound only to treatment-induced dead
tumor cells for these two cancer lines.
Validation of Conjugation and Radiolabeling of
Immunoreactive chDAB4
After DFO conjugation to the chDAB4 mAb, analysis by
electrospray ionization mass spectrometry revealed the
conjugate had between 0 and 3 chelators attached per mAb
with an average of 0.8 H3DFO per antibody (Fig. 2a).
Radiolabeling of chDAB4 with [89Zr]ZrIV, resulted in
specific activities ranging from 115 to 170 MBq/mg and
G1 % free [89Zr]ZrIV in the preparation by ITLC (Fig. 2b),
with the immunoreactive fraction being 88.3 % as deter-
mined by the Lindmo assay (Fig. 2c). The binding of
unconjugated, conjugated or radiolabeled versions of
chDAB4 to the La/SSB peptide epitope measured by ELISA
were similar (Fig. 2c), with the dissociation constant (Kd)
values for unconjugated chDAB4, DFO-conjugated
chDAB4 and the radioimmunoconjugate [89Zr]Zr-DFO-
chDAB4 being 17.8 ± 2.8, 19.7 ± 2.6, and 23.1 ± 3.9
pmol/L (± SEM) respectively (Fig. 2c). These data show that
binding affinities were minimally altered by the processes of
DFO conjugation or radiolabeling.
Characterization of the Immune Effector
Properties of chDAB4
We sought to mitigate the risk of retaining immune effector
functions of CDC and ADCC inherent in a version of
chimeric DAB4 with a wildtype Fc region, which might
exert untoward bystander pro-inflammatory effects, by
introducing the K322A mutation [38] in the Fc region of
chDAB4. Then, we investigated the immunologic properties
of this unconjugated and K322A mutant version of chDAB4
918 Liapis V. et al.: APOMAB® Detects Tumour Cell Death Following Chemotherapy in vivo
using in vitro assays for CDC, ADCC and cytokine release.
Although the anti-CD20 targeting mAb rituximab initiated
the complement-mediated lysis of CD20+ Raji target cells
but not CD20- Jurkat cells, neither of the other chimeric
mAbs, chDAB4, and cetuximab, both of which contain a
huIgG1 Fc domain, resulted in cytotoxicity of the Raji cells
(Fig. 2d). Next, we used a reporter assay to measure the
intracellular signaling that would be induced in cells
mediating ADCC after exposure to antibody-bound target
cells. In contrast to the induction of the reporter signal after
exposure to rituximab-bound Raji cells, there was no signal
induction either using as targets, the viable Raji or H460
cells that show minimal or no binding by chDAB4, or the
permeabilized H460 cells that show high binding by
chDAB4 (Fig. 2d). Results of the in vitro cytokine release
assay (Supplementary Figure 1) show a relative lack of
reactivity of chDAB4 among PBMCs of 5 normal subjects
and, in particular, no chDAB4-dose-dependent elevations in
inflammatory cytokine levels were observed. One subject
(1), who was found to have had a concurrent systemic viral
infection, had an increase in IL-1β, IL-6, IL-10, and TNF-α
following chDAB4 incubation which appeared to be
inversely proportion to chDAB4 concentration used. An-
other subject (2) had elevations of IL-6 and TNF-α that were
independent of chDAB4 concentration.
[89Zr]Zr-chDAB4 Biodistribution and Tumor
Uptake in Untreated and Cisplatin Treated Mice
Bearing Subcutaneous Xenografts of the Human
H460 Lung Cancer Cell Line
Mice bearing subcutaneous xenograft model of H460 lung
cancer were either untreated or treated with cisplatin (Day
Fig. 1. chDAB4 binds to human A2780 ovarian cancer and H460 lung cancer cells after cisplatin treatment in vitro. a. A2780
and H460 cell lines were treated with increasing doses of cisplatin for 48 h and cell death (PI+) and chDAB4 binding analyzed by
flow cytometry. b. Increasing the concentration of cisplatin resulted in significantly increased cell death and chDAB4 binding for
both A2780 and H460 cells (pG0.0001 for 10 μg/mL cisplatin compared to no cisplatin). c. After subtracting the mean
fluorescence intensity (MFI) of binding of Intragram P used as the isotype control, the MFI of chDAB4 bound to PI+ H460 or
A2780 cells increased with cisplatin treatment. All data points are means ± SEM.
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Fig. 2. Conjugation of chDAB4, immunoreactivity of unconjugated and conjugated chDAB4 and the lack of immune effector
functions of conjugated chDAB4. a. Mass spectrometry shows 0–3 attachments of DFO with an average of 0.8 chelator
molecules per antibody. b. ITLC results show G1 % free [89Zr]ZrIV in the preparation. c. Left; Results of a representative Lindmo
assay, which shows an immunoreactive fraction (IRF) value of 88.3 % for the [89Zr]Zr-labeled DFO-conjugate of chDAB4. c.
Right; Binding to the La peptide epitope by unconjugated chDAB4 and by [89Zr]Zr-labeled or unlabeled DFO-conjugates of
chDAB4 as measured by ELISA (n = 3). d. Left; Mean % cell survival of CD20+ Raji cells or CD20¯ Jurkat cells in the CDC assay
in response to varying concentrations of chimeric monoclonal antibodies (mAbs) (n = 3). d. Right; Mean fold induction of
reporter gene expressed by effector Jurkat cells in the ADCC assay in response to the chimeric mAbs, chDAB4 and CD20-
specific rituximab. Target cells are CD20+ Raji or CD20¯ H460 cells. The H460 cells were either viable or permeabilized (perm.)
to expose the La/SSB protein (n = 3).
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1) followed the next day (Day 2) by injection of [89Zr]Zr-
chDAB4. To demonstrate the antigen specificity of the
tumor uptake of [89Zr]Zr-chDAB4, a group of mice
received a five-fold molar excess (250 μg) of unlabeled,
cold chDAB4 1 h before the [89Zr]Zr-chDAB4 injection
to act as a blocking control. Cisplatin treatment signifi-
cantly reduced tumor size as measured by biolumines-
cence imaging (Fig. 3a), caliper measurements, and tumor
weights at the end of study (Fig. 3b). As shown in Fig.
3c, data obtained over the 6-day PET imaging period
demonstrated the greatest tumor uptake on Day 3 of
[89Zr]Zr-chDAB4 as percentage injected activity per gram
(%IA/g ± SEM) in cisplatin-treated mice (26.9 ± 2.2)
compared to cisplatin-treated mice given prior blocking
antibody (13.0 ± 0.7), or untreated mice (17.6 ± 1.6).
Moreover, it is also apparent from Fig. 3c that tumor
uptake of [89Zr]Zr-chDAB4 after cisplatin treatment
significantly increased on Days 3 and 4 before tumor
growth delay became apparent (Fig. 3b), and all while
PET images during the week post-injection showed
diminishing background uptake (Fig. 3c). In vivo antigen
blockade [44] appreciably reduced tumor accumulation of
[89Zr]Zr-chDAB4 and prolonged blood-pool radioactivity
(Fig. 3c) thereby confirming that the tumor targeting by
[89Zr ]Zr -chDAB4 was spec i f i c . The phys ica l
biodistribution data obtained at the completion of the study
(Fig. 3d) showed significantly greater mean tumor uptake of
[89Zr]Zr-chDAB4 in cisplatin-treated mice measured as %IA/g
± SEM of 26.7 ± 7.6 compared to 7.7 ± 1.8 for cisplatin-treated
mice given prior cold chDAB4 mAb as a blocking control, but
not significantly different compared to untreated mice with
%IA/g ± SEM of 13.1 ± 2.6. Consistent with this result, we
found that the mean %IA/g ± SEM of 9.4 ± 0.7 in blood of
cisplatin-treated mice after prior blocking antibody was higher
than in cisplatin-treated mice (4.3 ± 2.0) and in untreated mice
(2.1 ± 1.3).
Conversely, prior blocking antibody led to a lower mean
bone uptake ± SEM of 11.5 ± 0.5 %IA/g compared to %IA/g
values of 20.7 ± 2.3 and 19.5 ± 2.1 in cisplatin-treated mice
and untreated mice, respectively. Interestingly, in cisplatin-
treated mice pre-administered blocking antibody, mean
splenic uptake ± SEM as %IA/g of radiolabeled antibody
was 63.2 ± 7.3 and significantly reduced compared to 83.7 ±
13.6 in mice treated with cisplatin alone; and 109.3 ± 12.9 in
untreated mice.
[89Zr]Zr-chDAB4 Biodistribution in Untreated
and Cisplatin-Treated Mice Bearing Subcutane-
ous and Ascitic Xenografts of the Human A2780
Ovarian Cancer Cell Line
In the subcutaneous A2780 ovarian cancer xenograft model,
cisplatin treatment significantly controlled tumor growth
compared to untreated control mice as measured using
bioluminescence imaging (Fig. 4a). The significant
antitumor activity of cisplatin was also evident both as
reduced tumor growth by caliper measurements and lower
ex vivo tumor weights at the end of study (Fig. 4b), with the
mean tumor weight of cisplatin-treated mice being 196 ±
82.1 mg compared to 563 ± 60.8 mg in untreated mice.
Mice were imaged daily after injection of [89Zr]Zr-
chDAB4 on Day 1, the day after chemotherapy administra-
tion, and representative PET scans together with the extent
of tumor uptake determined by PMOD PET image analysis
are shown in Fig. 4c. These data show that tumor uptake of
[89Zr]Zr-chDAB4 significantly increased in treated mice at
2–3 days post-[89Zr]Zr-chDAB4 injection, which corre-
sponds to 3 and 4 days after chemotherapy (given on Day
0). In Fig. 4c, the mean tumor uptake as %IA/g ± SEM at 2–
3 days post-[89Zr]Zr-chDAB4 injection was 49.3 ± 3.1 and
49.3 ± 3.7, respectively, for cisplatin-treated mice compared
to 37.9 ± 3.9 and 37.6 ± 3.9, respectively, for untreated
mice. Again, this tumor uptake of [89Zr]Zr-chDAB4 in
cisplatin-treated mice preceded the later observed delay in
tumor growth (Fig. 4a).
Organ assay at the completion of the study showed
elevated, but not statistically significant, tumor accumulation
in cisplatin-treated mice, with no significant differences in
uptake in normal tissues (Fig. 4d).
A2780 tumor cells, which can also be grown as ascitic
tumors, were given by intraperitoneal injection to NSG mice
to reproduce the pattern of tumor growth commonly seen in
ovarian cancer patients. Bioluminescence imaging was used
to evaluate tumor growth because the ascitic tumors are not
easily palpable. Representative whole-body bioluminescence
images (Fig. 5a) and quantification of these data showed a
significant reduction in disease burden compared to un-
treated mice, particularly within the first few days after
chemotherapy. MRI imaging also confirmed the presence of
an intraperitoneal tumor and reduced tumor size after
cisplatin treatment. At the completion of the experiment,
mean tumor weight (± SEM) in cisplatin-treated mice was
smaller 168.8 mg (± 92.1) than in untreated mice 233.3 mg
(± 173.9), but did not reach statistical significance (Fig. 5b).
Representative PET slices and the biodistribution of
[89Zr]Zr-chDAB4 (Fig. 5c) indicated that tumor accumula-
tion of [89Zr]Zr-chDAB4 tended to be higher in cisplatin-
treated mice, 30.3 ± 11.5 %IA/g, than in untreated mice,
13.3 ± 2.2 %IA/g, but did not reach statistical significance.
Discussion
This study shows that radiolabeling chDAB4 with
Zirconium-89 enables noninvasive and longitudinal study
of its biodistribution in live mice bearing lung or ovarian
cancer xenografts. In current clinical oncology practice,
interim responses to platinum-based chemotherapy may not
be determined by CT scanning until after 2 or 3 cycles of
chemotherapy (equivalent to 9 or 12 weeks), which may
mean that patients experience chemotherapy side effects
without realizing a clinical benefit [45]. Our whole-body
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Fig. 3. Biodistribution of [89Zr]Zr-chDAB4 in mice bearing subcutaneous xenografts of H460 human lung cancer. a.
Representative longitudinal whole-body bioluminescence images of a single mouse from each group (n = 5) are shown. Color
scales indicates relative luminescence (photon flux). The line graph shows relative tumor growth measured as the average
tumor bioluminescence signal over time (expressed as mean photon counts per second per cm2). b. The tumor volume
calculated from caliper dimensions on Days 0, 3, and 6 (top panel) and the weight of tumors removed at end of study on Day 7
(bottom panel). c. Representative spatial Maximum Intensity Projections of whole-body PET images of a single mouse from
each group are shown. Arrows at Day 7 time point indicate tumors in right flank of each mouse. Tumor uptake of [89Zr]Zr-
chDAB4 during the experiment was quantified and expressed as the percentage injected activity per gram (%IA/g) using
PMOD® software (bottom panel). d. Organs were removed on Day 7 and the biodistribution of [89Zr]Zr-chDAB4 was measured
using a HIDEX counter (right-hand panel). All data points are means ± SEM and P values were determined by two-way ANOVA.
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Fig. 4. Biodistribution of [89Zr]Zr-chDAB4 in mice bearing subcutaneous xenografts of A2780 human ovarian cancer. a.
Representative longitudinal whole-body bioluminescence images of a single mouse from each group (n = 5) are shown. Color
scales indicate relative luminescence (photon flux). The line graph shows average tumor bioluminescence signal over time,
expressed as mean photon counts per second per cm2. b. Tumor volume by caliper measurement and tumor weights at the
end of study on Day 8. Representative longitudinal whole-body PET images of tumor-bearing mice after i.v.i administration of
the [89Zr]Zr-chDAB4 radioconjugate on Day 1. c. Relative extent of tissue uptake of activity is shown in the Maximum Intensity
Projections of the whole body PET images according to the color scale. Arrows at Day 8 indicate tumors in right flank of each
mouse. Tumor uptake of the [89Zr]Zr-chDAB4 radioconjugates during the course of the experiment was quantified and
expressed as the percentage injected activity per gram (%IA/g) using the PMOD® software. d. Organs were removed on Day 8
and the biodistribution of [89Zr]Zr-chDAB4 was measured using a Hidex counter. P values were measured by two-way ANOVA.
All data points are means ± SEM.
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Fig. 5. Biodistribution of [89Zr]Zr-chDAB4 in mice bearing ascitic tumors of A2780 human ovarian cancer. a. Representative
longitudinal whole-body bioluminescence images of single mice from each group (n = 3) are shown (top panel). Color scales
indicate relative luminescence (or photon flux). Line graph shows average tumor bioluminescence signal over time, expressed
as mean photon counts per second per cm2(bottom panel). b. At the end of the study on Day 10, MRI scans taken of the same
pair of mice show intraperitoneal tumors (arrows) and tumors were removed and weighed. c. Representative longitudinal
Maximum Intensity Projections of whole-body PET images of a single mouse from each group showing the relative extent of
tissue uptake of activity are shown. Arrows at Day 10 time point indicate tumors in right flank of each mouse. In the upper
control panel, the arrow indicates a PET signal void, which corresponds to the tumor arrowed on the MRI scan. In the lower
treatment panel, the arrow marks uptake by the shrunken peritoneal tumor. Organs were removed on Day 10 and the
biodistribution of [89Zr]Zr-chDAB4 was measured using a Hidex counter. All data points are means ± SEM. P values were
measured by two-way ANOVA.
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PET imaging studies in mice bearing cisplatin-responsive
human ovarian and lung cancers [46, 47] provide preclinical
proof of concept for [89Zr]Zr-labeled chDAB4 as a tumor-
specific marker of postchemotherapy cell death, which
indicates a tumor response to treatment earlier than that
apparent later as tumor growth delay.
As shown in Fig. 1, cisplatin treatment induces dose-
dependent binding of chDAB4 to dead PI+ tumor cells
in vitro, which manifests both as an increasing proportion of
chDAB4-bound dead cells as well as an increasing amount
of chDAB4 that each dead tumor cell binds. This observa-
tion is similar to the time-dependent increases in both the
number of PI+ cells bound by DAB4 and per cell binding of
DAB4, which have been observed in previous in vitro and
in vivo studies [27, 31]. Here, however, we expect that this
cisplatin dose-dependent increase in tumor cell death
represents an accelerating process of post-apoptotic necrosis
of which chDAB4 binding provides a sensitive measure of
both its extent and intensity. Although we do not fully
understand this phenomenon, based on our previous studies
we hypothesize that the cellular epitope of La/SSB becomes
increasingly available in vivo for chDAB4 binding during
the process of post-apoptotic necrosis [30].
The postchemotherapy patterns of tumor uptake observed
with [89Zr]Zr-labeled chDAB4 in the animal biodistribution
studies are consistent with results of previous biodistribution
studies in murine tumor models using 14C-, 111In-, 90Y-,
177Lu- or 227Th-labeled versions of the parental murine
DAB4 mAb [27, 31]. In these studies, postchemotherapy
tumor accumulation of DAB4 was rapid, antigen-specific
and associated with the extent of chemotherapy-induced
tumor cell death. Notwithstanding the effect of the prior step
of DNA-damaging chemotherapy on tumor uptake of
DAB4, there was no evident accumulation of DAB4 in
chemo-sensitive normal tissues such as intestine.
The observed uptake of chDAB4 within tumors of
untreated mice results from the presence of spontaneously
apoptotic and necrotic tumor cells, which are often located
within the necrotic tumor core and which are a common
pathophysiologic feature of solid tumors. It is likely that
many of these necrotic tumor cells result from the death of
hypoxic tumor cells as we have shown previously [31].
Using the highly chemosensitive syngeneic murine EL4
lymphoma model where chemotherapy is known to induce
tumor cell apoptosis, we showed that the greatest and most
intense uptake of DAB4 occurred in tumor cells dying as a
result of chemotherapy rather than as a result of spontaneous
necrosis [15]. In the current study, however, we selected the
human H460 and A2780 tumor xenografts to better represent
relatively chemoresistant human lung and ovarian carcino-
mas, respectively.
Our investigation of antibody drug conjugates of
chDAB4 demonstrated that chDAB4-bound dead lung
cancer cells could be phagocytosed in vitro by macrophages
and suggested that similar macrophage-mediated processing
of chDAB4 may occur in vivo [16, 17]. The reduced bone
uptake of [89Zr]ZrIV after prior blockade with unlabeled
chDAB4 indicates that less free bone-seeking [89Zr]ZrIV [48]
is generated within the body of each mouse and this result
may thus help to explain the higher blood activity level.
These data suggest that catabolism of [89Zr]Zr-labeled
chDAB4 is required to release free or chelator-bound
[89Zr]ZrIV and we hypothesize that tumor-associated macro-
phages (TAMs) are likely to be one of the major
catabolizing cell types. In our recent study, we found some
support for this hypothesis.
Tumor-bearing mice, which had been depleted of
macrophages, were observed to have significantly less tumor
accumulation of [89Zr]Zr-chDAB4 [17]. Zirconium-89 is a
residualizing radionuclide, meaning that after internalization
of the cell surface molecule targeted by a [89Zr]Zr-labeled
mAb, the radiometal with or without its chelator is trapped
inside the cell [49]. In the case of [89Zr]Zr-labeled chDAB4,
our data indicate that TAMs are responsible for tumor
residualization of [89Zr]ZrIV [17].
After administration of [89Zr]Zr-labeled chDAB4 equiv-
alent to a protein mass of between 50 μg and 75 μg, we
observed bone uptake of [89Zr]ZrIV in each of the three
tumor models irrespective of the use of chemotherapy.
Others have shown that administration of as little as 0.31
MBq/5μg [89Zr]Zr-labeled DS-8273a, which is a death
receptor 5 targeting antibody, results in double the bone
uptake of radionuclide compared to 111In-labeled DS-8273a
[50]. Moreover, bone uptake of [89Zr]ZrIV after administra-
tion of [89Zr]Zr-labeled mAbs can confound the interpreta-
tion of immunoPET images by potentially creating false
positive osseous lesions [51]. In addition, in all three
xenograft models, we observed significant splenic accumu-
lation of radiolabel regardless of prior chemotherapy, which
has been shown in other studies of immuno-incompetent
NSG mice that had received radiolabeled antibodies [52–
54].
The commercially available DFO-pPhe-NCS bifunctional
chelator used in this study may have reduced in vivo stability
[55, 56], thus contributing to bone accumulation of activity.
Hence, the stability of the chelator together with the
antibody concentration and labeled radioactivity remain
important considerations in planning clinical applications
of [89Zr]Zr-labeled mAbs [57]. In this respect, new chelators
are being developed that may improve the stability and
biodistribution of [89Zr]Zr-labeled mAbs such as [89Zr]Zr-
chDAB4, which can generate free [89Zr]ZrIV, resulting in its
uptake by bone. For example, Donnelly et al. compared their
novel chelator, DFO-Sq, which is a squaramide ester
derivative of DFO-pPhe-NCS, to DFO-pPhe-NCS using
the HER2-targeting antibody, trastuzumab, and showed
improved radiolabeling efficiency and PET imaging charac-
teristics resulting from use of the DFO-Sq chelator [58].
Similarly, in a study of [89Zr]Zr-chDAB4, we found that
DFO-Sq as a chelator led to better in vitro and in vivo
stability and PET imaging quality than DFO-pPhe-NCS
[41]. Another recent study confirmed the very good shelf
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stability and high chemical purity of a [89Zr]Zr-labeled
immunoconjugate employing the DFO-Sq chelator [59].
In summary, we used [89Zr]Zr-chDAB4 immunoPET in
mice bearing tumor xenografts of lung and ovarian cancer to
show a specific, significant and early increase in
postchemotherapy tumor binding of this necrotic
radioligand, which pre-empted later tumor growth delay.
The results of the in vitro CDC, ADCC, and cytokine release
assays [60] demonstrate that the chimeric version of DAB4,
which contains the K322A mutation in the CH2 domain of
its huIgG1 Fc [38], lacks significant immune effector
activity that might compromise its safety as a clinical
radiodiagnostic agent. Therefore, the favorable
immunotargeting and immunological profile of [89Zr]Zr-
chDAB4 demonstrated in this study together with improved
PET imaging and stability characteristics exhibited by the
[89Zr]Zr-labeled DFO-Sq conjugate of chDAB4 [57] culmi-
nated in our decision to use the [89Zr]Zr-labeled DFO-Sq
conjugate of chDAB4 in our currently open phase 1
immunoPET/CT trial ( ANZCTR No. 12620000622909).
Although this clinical study is in progress, we show
preliminary PET/CT data in two metastatic lung cancer
patients who were not having concurrent anticancer treat-
ment but who had FDG-avid metabolically active metastases
(Supplementary Figure 2). Although these two patients
lacked tumor uptake of [89Zr]Zr-DFO-Sq-chDAB4, as we
have shown preclinically [14, 15], we hypothesize that this
radiodiagnostic agent is sufficient to discern those malignant
lesions that are responding to treatment by their extent of
tumor uptake of [89Zr]Zr-DFO-Sq-chDAB4.
Of potential clinical utility, [89Zr]Zr-labeled chDAB4 can
be used in radiation dosimetry [61] in order to determine
subsequent dosing regimens for chDAB4 to be employed in
clinical antibody radioconjugate therapy. Now that platinum-
based chemotherapy is a component of standard frontline
chemo-immunotherapy regimens for advanced NSCLC
patients [62, 63], tumor-targeted internal radiotherapy such
as that delivered by chDAB4 may lead to interactions with
immune checkpoint inhibitor therapy and potentially pro-
mote the antitumor activity of the combination regimen [64].
In conclusion, although we provide preclinical proof-of-
concept for [89Zr]Zr-chDAB4 immunoPET as a
radiodiagnostic method to enable early detection of interim
tumor responses to the platinum-based chemotherapy, we
recognize that our results show that the degree of chDAB4
uptake by tumors of untreated mice may limit interpretation
of treatment effects and thus the potential clinical utility of
our technique. In our current phase 1 clinical immunoPET
trial, only a single postchemotherapy dose of [89Zr]Zr-DFO-
Sq-chDAB4 will be administered because as a chimeric
antibody, chDAB4 may elicit untoward immune reactions.
However, in future clinical studies we will mitigate this risk
by using a humanized form of DAB4 so that we can also
address the question of relative postchemotherapy tumor
uptake of the radioligand by comparing its biodistribution
between pre- and post-chemotherapy injections.
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